China’s vaccine project offers new prospects of global collaboration

Peoples Health Dispatch | July 01, 2021

In May and June 2021, the World Health Organization’s (WHO) Strategic Advisory Group of Experts (SAGE) listed two Chinese COVID-19 vaccines – Sinopharm’s  ‘BBIBP-CorV-2’ and Sinovac’s ‘CoronaVac’ – for emergency use and issued interim policy recommendations.

The two vaccines, which were among the first to be developed globally, met the requirement of 50% efficacy needed for WHO approval. Though further data is expected, the existing preliminary data shows that Sinovac’s vaccine has an efficacy of 51% against symptomatic COVID-19 infection and 100% against severe infection, while Sinopharm’s has an efficacy of 79% against symptomatic cases and hospitalization.

Read More »